Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Koyama, Shohei, Akbay, Esra A., Li, Yvonne Y., Herter-Sprie, Grit S., Buczkowski, Kevin A., Richards, William G., Gandhi, Leena, Redig, Amanda J. +18 more·2016·Nature Communications

DOI 10.1038/ncomms10501

Cited by (1,000)

Items 401–500 of 1,000

4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers
Karolina I. Woroniecka, Kristen Elizabeth Rhodin, Cosette A. Dechant, Xiuyu Cui, Pakawat Chongsathidkiet, Daniel S. Wilkinson, Jessica Waibl Polania, Luis A Sanchez-Perez, Peter Edward Fecci · 2019 · Clinical Cancer Research
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
Borelli, Beatrice, Antoniotti, Carlotta, Carullo, Martina, Germani, Marco Maria, Conca, Veronica, Masi, Gianluca · 2022 · Cancers
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
Zhen‐Bin Qiu, Zi‐Hao Chen, Chao Zhang, Wen‐Zhao Zhong · 2019 · Experimental Hematology and Oncology
Red Blood Cell-Mimic Nanocatalyst Triggering Radical Storm to Augment Cancer Immunotherapy
Jiong Li, Sijia Wang, Xinyi Lin, Yanbing Cao, Zhixiong Cai, Jing Wang, Zhenxi Zhang, Xiaolong Liu, Ming Wu, Cuiping Yao · 2022 · Nano-Micro Letters
Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
Stefanie Hiltbrunner, Lena Cords, Sabrina Kasser, Sandra Nicole Freiberger, Susanne Kreutzer, Nora C. Toussaint, Linda Grob, Isabelle Opitz, Michael Messerli, Martin Zoche et al. · 2023 · Nature Communications
Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance
Chao-Jia Chen, Fang-Cheng Zhao, Jia-Li Peng, Di Zhao, Li-Yun Xu, Huayu Li, Shuai-Ya Ma, Xueqi Peng, Xue Sheng, Yang Sun et al. · 2024 · Cell Reports Medicine
Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective
Negar Sadat Sherafat, Ali Keshavarz, Amirhossein Mardi, Amirmohammad Mohammadiara, Mojtaba Aghaei, Leili Aghebati Maleki, Mohammad Hossein Mohammadi · 2025 · Clinical and Experimental Medicine
PD-L1 expression in medulloblastoma: an evaluation by subgroup
Allison M. Martin, Christopher J. Nirschl, Magdalena J. Polanczyk, W Robert Bell, Thomas R. Nirschl, Sarah Harris‐Bookman, Jillian A. Phallen, Jessica L Hicks, Daniel Martínez, Aleksandra Ogurtsova et al. · 2018 · Oncotarget
Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease
Hanna R. Kemeny, Aladine A. Elsamadicy, Samuel Harrison Farber, Cosette D. Champion, Selena Lorrey, Pakawat Chongsathidkiet, Karolina I. Woroniecka, Xiuyu Cui, Steven H. Shen, Kristen Elizabeth Rhodin et al. · 2019 · Clinical Cancer Research
Recent advances in nanosized drug delivery systems for overcoming the barriers to anti-PD immunotherapy of cancer
Xiaochen Liu, Dangge Wang, Pengcheng Zhang, Yaping Li · 2019 · Nano Today
Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients
Devayani Machiraju, Melanie Wiecken, Nina Lang, Ingrid Hülsmeyer, Jasmin Roth, Timo E. Schank, Rosa Eurich, Niels Halama, Alexander Enk, Jessica C. Hassel · 2021 · OncoImmunology
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
Jordan W. Conway, Robert V. Rawson, Serigne Lo, Tasnia Ahmed, Ismael A. Vergara, Tuba Nur Gide, Grace Heloise Attrill, Matteo Salvatore Carlino, Robyn P.M. Saw, John F. Thompson et al. · 2022 · Journal for ImmunoTherapy of Cancer
Identification of a small-molecule Tim-3 inhibitor to potentiate T cell–mediated antitumor immunotherapy in preclinical mouse models
Shuaiya Ma, Ye Tian, Jiali Peng, Chaojia Chen, Xueqi Peng, Fabao Zhao, Zhenyu Li, Mengzhen Li, Fangcheng Zhao, Xue Sheng et al. · 2023 · Science Translational Medicine
Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion
Yiran Wu, Yuchen Wu, Zhengyu Gao, Weixing Yu, Long Zhang, Fangfang Zhou · 2026 · Signal Transduction and Targeted Therapy
Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors
Floris F. Dammeijer, Sai Ping Lau, Casper H.J. van Eijck, Sjoerd H. van der Burg, Joachim G.J.V. Aerts · 2017 · Cytokine & Growth Factor Reviews
Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
Mengjia Song, Xinfeng Chen, Liping Wang, Yi Zhang · 2018 · Chinese Journal of Cancer Research
Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma
Margaret Ottaviano, Sabino De Placido, Paolo A. Ascierto · 2019 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
Pan-cancer genomic analysis links 3’UTR DNA methylation with increased gene expression in T cells
Michael H. McGuire, Shelley M. Herbrich, Santosh K. Dasari, Sherry Y. Wu, Ying Wang, Rajesha Rupaimoole, Gabriel Lopez‐Berestein, Keith Baggerly, Anil K. Sood · 2019 · EBioMedicine
Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints
Kristian Michael Hargadon · 2020 · Clinical and Translational Medicine
Emerging principles of brain immunology and immune checkpoint blockade in brain metastases
Jawad Fares, Ilya V. Ulasov, Peter S. Timashev, Maciej S. Lesniak · 2021 · Brain
Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
Yue Chen, Haoyue Hu, Xianglei Yuan, Xue Fan, Chengda Zhang · 2022 · Frontiers in Immunology
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
Solange Peters, Luis G Paz-Ares, Roy S. Herbst, Martin Reck · 2022 · Journal for ImmunoTherapy of Cancer
Enhanced development of functional human NK cells in NOD‐ scid‐IL2rg null mice expressing human IL15
Ken‐Edwin Aryee, Lisa M. Burzenski, Li‐Chin Yao, James Keck, Dale L. Greiner, Leonard D. Shultz, Michael A. Brehm · 2022 · The FASEB Journal
Targeting tumor-infiltrating tregs for improved antitumor responses
Diyuan Qin, Yugu Zhang, Pei Shu, Yanna Lei, Xiaoyu Li, Yongsheng Wang · 2024 · Frontiers in Immunology
Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance
Bhargavi Pulluri, Abhijeet Kumar, Montaser F. Shaheen, Joanne Jeter, Srinath Sundararajan · 2017 · Pharmacological Research
Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response
Ashley Plant, Shohei Koyama, Claire E. Sinai, Isaac H. Solomon, Gabriel Kenneth Griffin, Keith Lloyd Ligon, Pratiti Bandopadhayay, Rebecca A. Betensky, Ryan Emerson, Glenn Dranoff et al. · 2018 · Journal of Neuro-Oncology
Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer
Nicholas C. Borcherding, Ryan H. Kolb, Jodi A. Gullicksrud, Praveen Vikas, Yuwen Zhu, Weizhou Zhang · 2018 · Journal of Molecular Biology
TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo
Srimoyee Ghosh, Geeta Sharma, Jon Travers, Sujatha Kumar, Justin Choi, H. Toni Jun, Marilyn R. Kehry, Sridhar Ramaswamy, David Jenkins · 2018 · Molecular Cancer Therapeutics
Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC
Yawen Dong, Jeffrey Sum Lung Wong, Ryohichi Sugimura, Ka On Lam, Bryan K. Li, Gin Wai Kwok, Roland Ching-Yu Leung, Joanne Wing Yan Chiu, Tan To Cheung, Thomas C. C. Yau · 2021 · Cancers
Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities
Davood Bashash, Zahra Zandi, Bahareh Kashani, Atieh Pourbagheri‐Sigaroodi, Sina Salari, Seyed Hamidollah Ghaffari · 2021 · Journal of Cellular Physiology
Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy
Elnaz Rouzbahani, Jamal Majidpoor, Sajad Najafi, Keywan Mortezaee · 2022 · Biomedicine & Pharmacotherapy
High numbers of PDCD1 (PD-1)-positive T cells andB2Mmutations in microsatellite-unstable colorectal cancer
Jonas Janikovits, Meike Müller, Julia Krzykalla, Sandrina Körner, Fabian Echterdiek, Bernd Lahrmann, Niels Grabe, Martin A. Schneider, Axel Benner, Magnus von Knebel Doeberitz et al. · 2017 · OncoImmunology
A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment
Anje Cauwels, Sandra Van Lint, Geneviève Garcin, Jennyfer Bultinck, Franciane Paul, Sarah Gerlo, José Van der Heyden, Yann Bordat, Dominiek Catteeuw, Lode De Cauwer et al. · 2017 · OncoImmunology
Drug response to PD-1/PD-L1 blockade: based on biomarkers
Qi Chen, Tianhe Li, Wentao Yue · 2018 · OncoTargets and Therapy
Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine
Florent Petitprez, Cheng‐Ming Sun, Laetitia Lacroix, Catherine Sautès‐Fridman, Aurélien de Reyniès, Wolf H. Fridman · 2018 · Frontiers in Oncology
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Morgane Denis, M. Duruisseaux, Marie Brevet, Charles Dumontet · 2020 · Frontiers in Immunology
Emerging CAR T Cell Strategies for the Treatment of AML
Paresh Vishwasrao, Gongbo Li, Justin C. Boucher, Diane Lynne Smith, Susanta Kumar Hui · 2022 · Cancers
The Landscape of Immunotherapy Resistance in NSCLC
Daniele Frisone, Alex Friedlaender, Alfredo Addeo, Petros K. Tsantoulis · 2022 · Frontiers in Oncology
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy
Saud Almawash · 2025 · Cancers
Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival
Geoffrey J. Markowitz, Lauren S. Havel, Michael J. P. Crowley, Yi Ban, Sharrell B. Lee, Jennifer S. Thalappillil, Navneet Narula, Bhavneet Bhinder, Olivier Elemento, Stephen T. C. Wong et al. · 2018 · JCI Insight
Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models
Steven A. Greenberg, Sek Won Kong, Evan Thompson, Stefano V. Gullà · 2019 · Oncotarget
Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma
Layal El Halabi, Julien Adam, Pauline Gravelle, Virginie Marty, Alina Danu, Julien Lazarovici, Vincent Ribrag, Jacques Bosq, Valérie Camara‐Clayette, Camille Laurent et al. · 2020 · Clinical Lymphoma Myeloma & Leukemia
Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
Laurens E. Franssen, Claudia A.M. Stege, Sonja Zweegman, Niels W.C.J. van de Donk, Inger S. Nijhof · 2020 · Journal of Clinical Medicine
Immunotherapy in Breast Cancer: When, How, and What Challenges?
Beatriz Henriques, Fernando Mendes, Diana F. Martins · 2021 · Biomedicines
Strategies targeting tumor immune and stromal microenvironment and their clinical relevance
Mengying Hu, Leaf Huang · 2022 · Advanced Drug Delivery Reviews
Intracavitary Spraying of Nanoregulator‐Encased Hydrogel Modulates Cholesterol Metabolism of Glioma‐Supportive Macrophage for Postoperative Glioblastoma Immunotherapy
Yuanmin Dong, Jing Zhang, Yan Wang, Yulin Zhang, Daniella Rappaport, Zhenmei Yang, Maosen Han, Ying Liu, Zhipeng Fu, Xiaotian Zhao et al. · 2023 · Advanced Materials
A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
Erica T. Goddard, Jacob Fischer, Pepper S. Schedin · 2016 · Journal of Visualized Experiments
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Xinyu Yan, Shouyue Zhang, Yun Deng, Peiqi Wang, Qianqian Hou, Heng Xu · 2018 · Frontiers in Pharmacology
Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics
Enping Hong, Marina A. Dobrovolskaia · 2018 · Advanced Drug Delivery Reviews
The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine
Xinming Li, Mingdong Li, Meiying Huang, Qianyi Lin, Qiuping Fang, Jianjiang Liu, Xiaohui Chen, Lin Liu, Xuliang Zhan, Huisi Shan et al. · 2022 · Biomedicine & Pharmacotherapy
Rechallenge with Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma: A Narrative Review
Jin Li, Yu-Bo Liang, Qingbo Wang, Wan-Ling Luo, Xingming Chen, Yawhan Lakang, Zi-Sheng Yang, Jin-Xiang Zuo, Yu-Kai Li, Zhiwei Li et al. · 2025 · Liver Cancer
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, Wonyoung, Won, Taejoon, Daoud, Abdel, Čiháková, Daniela · 2024 · Frontiers in Immunology
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Ankita Mitra, Anoop Kumar, Nitin Purushottam Amdare, Rajiv Pathak · 2024 · Biology
The role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications
Yu Ma, Ting Wang, Xudong Zhang, Pinghan Wang, Fangyi Long · 2024 · Cell Death and Disease
Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers
Sandra Ortiz‐Cuaran, Jebrane Bouaoud, Andy Karabajakian, Jérôme Fayette, Pierre Saintigny · 2021 · Frontiers in Oncology
The Tumor Microenvironment of Colorectal Cancer Metastases: Opportunities in Cancer Immunotherapy
Yasmin Kamal, Stephanie L. Schmit, Hildreth Robert Frost, Christopher Ian Amos · 2020 · Immunotherapy
Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
Xingxiang Pu, Lin Wu, Dan Su, Weimin Mao, Bingliang Fang · 2018 · BMC Cancer
Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1
Andrea Botticelli, Silvia Mezi, Giulia Pomati, Bruna Cerbelli, Edoardo Cerbelli, Michela Roberto, Raffaele Giusti, Alessio Cortellini, Luana Lionetto, Simone Scagnoli et al. · 2020 · Frontiers in Immunology
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
Timothy Anthony Yap, Patricia Mucci LoRusso, Deborah J. L. Wong, Siwen Hu‐Lieskovan, Kyriakos P. Papadopoulos, Josefin-Beate Holz, Urszula B. Grabowska, Cristian Grădinaru, Kin-Mei Leung, Sylwia Marshall et al. · 2022 · Clinical Cancer Research
The innate immune architecture of lung tumors and its implication in disease progression
Simon Milette, Pierre Fiset, Logan A. Walsh, Jonathan David Spicer, Daniela F. Quail · 2019 · The Journal of Pathology
Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
Johanna Veldman, Lydia Visser, Anke van den Berg, Arjan Diepstra · 2019 · Cancer Treatment Reviews
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy, Dia, Gilmour, Cassandra, Patnaik, Sachin, Wang, Li Lily · 2023 · Frontiers in Immunology
Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy
Jonathan S. Kurman, Septimiu Dan Murgu · 2018 · Journal of Thoracic Disease
Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells
Timo Burster, Rebecca Traut, Zhanerke Yermekkyzy, Katja Mayer, Mike‐Andrew Westhoff, Joachim Bischof, Uwe Knippschild · 2021 · Frontiers in Cell and Developmental Biology
Immunotherapy of MSI Cancer: Facts and Hopes
Helen Catherine Wilbur, Dung Thi Le, Parul Agarwal · 2023 · Clinical Cancer Research
Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma
Maarten Alexander Ligtenberg, Yago Pico de Coaña, Taisia Shmushkovich, Yuya Yoshimoto, Iva Truxová, Yuan Yang, Monica Betancur-Boissel, Alexey V. Eliseev, Alexey D. Wolfson, Rolf W. Kiessling · 2018 · Molecular Therapy
Acquired resistance to cancer immunotherapy
Arianna Draghi, Christopher Aled Chamberlain, Andrew J.S. Furness, Marco Donia · 2018 · Seminars in Immunopathology
Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy
Eun Sook Lee, Jung Min Shin, Soyoung Son, Hyewon Ko, Wooram Um, Seok Ho Song, Jae Ah Lee, Jae Hyung Park · 2019 · Advanced Healthcare Materials
Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of 18F-FDG PET/CT
Amir Iravani, Rodney J. Hicks · 2020 · Journal of Nuclear Medicine
PTX3 mediates the infiltration, migration, and inflammation‐resolving‐polarization of macrophages in glioblastoma
Hao Zhang, Yifan Wang, Yihan Zhao, Tao Liu, Zeyu Wang, Nan Zhang, Ziyu Dai, Wantao Wu, Hui Cao, Songshan Feng et al. · 2022 · CNS Neuroscience & Therapeutics
Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer
Xianqiang Liu, Xiaowei Xi, Shengshan Xu, Hongyu Chu, Penghui Hu, Dong Li, Bin Zhang, Hejie Liu, Tianxiao Jiang, Zhuming Lu · 2024 · Frontiers in Immunology
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
Martin Reck, Nikolaj Frost, Solange Peters, Bernard A. Fox, Roberto Ferrara, Rajkumar Savai, Fabrice Barlési · 2025 · Nature Reviews Clinical Oncology
Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma
Yutaka Takahashi, Tomohiro Yasui, Keisuke Tamari, Kazumasa Minami, Keisuke Otani, Fumiaki Isohashi, Yuji Seo, Ryosuke Kambe, Masahiko Koizumi, Kazuhiko Ogawa · 2017 · PLoS ONE
Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients
Ryo Kato, Makoto Yamasaki, Shinya Urakawa, Kentaro Nishida, Tomoki Makino, Akiko Morimoto-Okazawa, Atsunari Kawashima, Kota Iwahori, Susumu Suzuki, Ryuzo Ueda et al. · 2018 · Cancer Immunology Immunotherapy
Exploiting NK Cell Surveillance Pathways for Cancer Therapy
Alexander D. Barrow, Marco Colonna · 2019 · Cancers
CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells
Orazio Fortunato, Dimas Carolina Belisario, Mara Compagno, Francesca Giovinazzo, Cristiano Bracci, Ugo Pastorino, Alberto L. Horenstein, Fabio Malavasi, Riccardo Ferracini, Stefania Scala et al. · 2020 · Frontiers in Immunology
Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)
Fuat Bicer, Catrina Kure, Ahmet Anıl Özlük, Bassel F. El‐Rayes, Mehmet Akce · 2023 · Current Oncology
Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives
Ilaria Salvato, Antonio Marchini · 2024 · Cancers
TUSC2 Immunogene Therapy Synergizes with Anti–PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras -Mutant Mouse Lung Cancer Models
Ismail Mustafa Meraz, Mourad Majidi, Xiaobo X. Cao, Heather Yan Lin, Lerong Li, Jing Wang, Veera Baladandayuthapani, David C. Rice, Boris Sepesi, Lin Ji et al. · 2018 · Cancer Immunology Research
The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression
Shengxiang Ren, Qinrui Tian, Nadav Amar, Hui Yu, Christopher J. Rivard, Charles Caldwell, Terry L. Ng, Megan M. Tu, Yiwei Liu, Dexiang Gao et al. · 2018 · Lung Cancer
The Identification of Immunological Biomarkers in Kidney Cancers
Antonio Lopez-beltran B, Vanessa Henriques, Alessia Cimadamore, Matteo Santoni, Liang Cheng C, Thomas Gevaert, Ana Blanca, Francesco Massari, Marina Scarpelli, Rodolfo Montironi · 2018 · Frontiers in Oncology
Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients
Estefanía Paula Juliá, Pablo Mandó, Manglio Rizzo, Gerardo Rubén Cueto, Florencia Tsou, Romina Luca, Carmen Sofía Pupareli, Alicia Bravo, Walter Astorino, José Mordoh et al. · 2019 · Cancer Immunology Immunotherapy
Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang
Junfu Ma, Yanxin Yao, Ye Tian, Kexin Chen, Ben Liu · 2022 · Biology of Sex Differences
CHI3L1 enhances melanoma lung metastasis via regulation of T cell co-stimulators and CTLA-4/B7 axis
Bing Ma, Suchitra Kamle, Bedia Akosman, Hina Khan, Chang-Min Lee, Chun Geun Lee, Jack Angel Elias · 2022 · Frontiers in Immunology
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
Kexun Zhou, Shuo Li, Yi Zhao, Ke Cheng · 2023 · Frontiers in Immunology
The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating
Yize Mao, Hui Xie, Min‐Yi Lv, Qiuxia Yang, Zeyu Shuang, Feng Gao, Shengping Li, Lina Zhu, Wei Wang · 2023 · Cancer Immunology Immunotherapy
The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy
Terhi Kärpänen, Johanna Olweus · 2017 · Frontiers in Immunology
Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
Weimin Lin, Miao Chen, Le Hong, Hang Zhao, Qianming Chen · 2018 · Frontiers in Oncology
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Yumeng Wang, Guiling Li · 2019 · Frontiers of Medicine
Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment
Zuzana Macek Jílková, Caroline Aspord, Keerthi Kurma, Anouck Granon, Christian Sengel, Nathalie Stürm, Patrice Noël Marche, Thomas Decaens · 2019 · Clinical and Translational Gastroenterology
Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma
Stefania De Lorenzo, Francesco Tovoli, Franco Trevisani · 2022 · Cancers
Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma
William H. Tomaszewski, Jessica Waibl Polania, Molly A. Chakraborty, Jonathan Perera, Jeremy J. Ratiu, Alexandra M. Hoyt-Miggelbrink, Donald Patrick McDonnell, Mustafa Khasraw, David M. Ashley, Peter Edward Fecci et al. · 2022 · Nature Communications
Resistance to immune checkpoint inhibitors and the tumor microenvironment
Shusuke Kawashima, Yosuke Togashi · 2022 · Experimental Dermatology
Immune checkpoint: The novel target for antitumor therapy
Xianghu Jiang, Guohong Liu, Yirong Li, Yunbao Pan · 2019 · Genes & Diseases
Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment
Min Yang, Wenwen Du, Lixian Yi, Shaoxian Wu, Chunyan He, Wensi Zhai, Cuihua Yue, Runzi Sun, Ashley V. Menk, Greg M. Delgoffe et al. · 2020 · OncoImmunology
Progress in Neoantigen Targeted Cancer Immunotherapies
Xuejiao Han, Xuelei Ma, Yang Li, Yu-quan Wei, Yong Peng, Xiawei Wei · 2020 · Frontiers in Cell and Developmental Biology
The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
Mazdak Ganjalıkhani-Hakemi, Morteza Jafarinia, Mahdieh Azizi, Mahsa Rezaeepoor, Orkhan Isayev, Alexandr V. Bazhin · 2020 · Frontiers in Oncology
Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages
Jingyi Zhou, Weiyu Wang, Qi Li · 2021 · Journal of Experimental & Clinical Cancer Research
Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects
Xin Wang, Jie Lu, Gaochao Guo, Jinming Yu · 2021 · Cell Death and Disease
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
Natasha B. Leighl, Mary Weber Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence Howard Schwartz, James Lloyd Wade, William Irvin, Sreekanth Reddy, Jeffrey Crawford et al. · 2021 · Journal for ImmunoTherapy of Cancer